Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis.

Cardiovascular Diabetology
Christian SonessonIngrid Gause-Nilsson

Abstract

A pre-specified meta-analysis of cardiovascular (CV) events from 21 phase 2b/3 dapagliflozin clinical trials was undertaken to characterise the CV profile of dapagliflozin. This showed no increase in CV risk with dapagliflozin compared with control (placebo or comparator treatment) with or without background glucose-lowering therapies. The analysis reported here aimed to characterise the CV profile of dapagliflozin in subgroups of patients in these 21 studies grouped by degree of CV risk, based on both baseline and in-study risk factors (including hypoglycaemic events), with a focus on major adverse CV events (MACE). Patients with type 2 diabetes, both overall and with different levels of CV risk, including CV disease (CVD) history, age and other CV risk factors, were analysed. A further analysis compared CV risk in patients who experienced a hypoglycaemic event prior to MACE and those who did not. Analyses were based on time to first event using a Cox proportional hazards model stratified by study comparing dapagliflozin versus control. In total, 9339 patients were included in this meta-analysis; 5936 patients received dapagliflozin 2.5-10 mg (6668 patient-years) and 3403 received control (3882 patient-years). Dapagliflozin is...Continue Reading

References

Jun 10, 2008·The New England Journal of Medicine·Anushka PatelFlorence Travert
Jun 10, 2008·The New England Journal of Medicine·UNKNOWN Action to Control Cardiovascular Risk in Diabetes Study GroupWilliam T Friedewald
Dec 19, 2008·The New England Journal of Medicine·William DuckworthUNKNOWN VADT Investigators
Dec 31, 2008·Diabetes Care·James F ListFred T Fiedorek
May 12, 2009·Nutrition, Metabolism, and Cardiovascular Diseases : NMCD·E MannucciN Marchionni
Oct 12, 2010·The New England Journal of Medicine·Sophia ZoungasUNKNOWN ADVANCE Collaborative Group
Mar 4, 2011·The New England Journal of Medicine·Sreenivasa Rao Kondapally SeshasaiUNKNOWN Emerging Risk Factors Collaboration
May 6, 2011·Diabetes Care·Eberhard StandlAntonio Ceriello
Feb 7, 2012·The American Journal of Medicine·Cheng-Chieh LinTsai-Chung Li
Feb 19, 2013·Diabetes Care·Sarah Stark CasagrandeCatherine C Cowie
May 15, 2013·Diabetes, Obesity & Metabolism·H J Lambers HeerspinkJ List
Aug 2, 2013·Diabetes Care·Antonio Ceriello, Eric S Kilpatrick
Aug 1, 2013·BMJ : British Medical Journal·Atsushi GotoMitsuhiko Noda
Aug 6, 2013·Diabetes, Obesity & Metabolism·J P H WildingUNKNOWN Dapagliflozin 006 Study Group
Sep 3, 2013·The New England Journal of Medicine·Benjamin M SciricaUNKNOWN SAVOR-TIMI 53 Steering Committee and Investigators
Sep 3, 2013·The New England Journal of Medicine·William B WhiteUNKNOWN EXAMINE Investigators
Sep 4, 2013·European Heart Journal·Linda G MellbinHertzel C Gerstein
Sep 13, 2013·Annals of Internal Medicine·Despoina VasilakouApostolos Tsapas
Oct 12, 2013·Diabetes/metabolism Research and Reviews·Mei ZhangShuangqing Li
Apr 18, 2014·The New England Journal of Medicine·Edward W GreggLinda Geiss
Dec 30, 2014·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Mar 22, 2016·Postgraduate Medicine·Helmut O Steinberg
Jun 29, 2016·Clinical & Translational Immunology·Michael J KraakmanAndrew J Murphy
Jun 17, 2016·Current Medical Research and Opinion·Niki KatsikiDimitri P Mikhailidis
Oct 27, 2016·Revista Española De Cardiología·Belén Dalama, Jordi Mesa
Jan 26, 2017·Expert Review of Clinical Pharmacology·Awadhesh Kumar Singh, Ritu Singh
Apr 5, 2017·Expert Opinion on Drug Metabolism & Toxicology·André J Scheen
Jan 20, 2017·Hypertension Research : Official Journal of the Japanese Society of Hypertension·Asadur RahmanAkira Nishiyama
Apr 23, 2017·Diabetes, Obesity & Metabolism·Ralph A DeFronzo
Feb 6, 2017·Cardiovascular Diabetology·James Xu, Rohan Rajaratnam
Jul 8, 2017·Expert Opinion on Pharmacotherapy·Niki KatsikiDimitri P Mikhailidis
Nov 30, 2016·Journal of Neurology, Neurosurgery, and Psychiatry·Konstantinos P ImprialosAsterios I Karagiannis
Jan 13, 2018·Diabetes, Obesity & Metabolism·Itamar RazStephen D Wiviott
Jan 11, 2018·Diabetes/metabolism Research and Reviews·Angelo AvogaroIldiko Lingvay
Mar 9, 2018·Heart Failure Reviews·Anne Pernille OfstadOdd Erik Johansen
Dec 23, 2017·BioMed Research International·Mona P NasrallahMarwan M Refaat
Sep 8, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Oct 7, 2017·Expert Review of Clinical Pharmacology·André J Scheen
Oct 19, 2017·Postgraduate Medicine·Sebastian Filippas-NtekouanMoses S Elisaf
Jul 6, 2018·Expert Opinion on Drug Safety·María Molina-VegaFrancisco J Tinahones
Aug 5, 2018·Journal of Cellular Physiology·Habib YaribeygiAmirhossein Sahebkar
Nov 30, 2018·Expert Review of Clinical Pharmacology·Syed Raza ShahSteven Roark
Nov 27, 2018·Expert Opinion on Drug Metabolism & Toxicology·Mattia GalliNadia Aspromonte
Jan 4, 2019·Circulation Research·Helena C Kenny, E Dale Abel
Mar 18, 2017·Clinical Journal of the American Society of Nephrology : CJASN·Sergei PetrykivHiddo J L Heerspink
Apr 22, 2019·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Nienke M A IdzerdaHiddo J L Heerspink
Jul 20, 2019·Kardiologiia·A M MkrtumyanN K Mishchenko
Dec 21, 2018·Endocrine, Metabolic & Immune Disorders Drug Targets·Oğuz AkkuşOnur Kaypaklı
Jul 13, 2017·Current Medical Research and Opinion·Serge Jabbour
May 6, 2019·Endocrine Reviews·Antonino Di Pino, Ralph A DeFronzo

❮ Previous
Next ❯

Methods Mentioned

BETA
coronary artery bypass

Software Mentioned

DECLARE

Related Concepts

Related Feeds

CV Disorders & Type 2 Diabetes

This feed focuses on the association of cardiovascular diseases in patients with type 2 diabetes.